Physician profile
Daniel E Chervony
NPI 1467515361
$18,851.19
in general payments reported to CMS, 2019-2025
29 companies · $2,629 in 2025
The $2,629 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,098 · 2020: $1,027 · 2021: $6,903 · 2022: $650 · 2023: $1,374 · 2024: $2,170 · 2025: $2,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,161 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,161.03 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $4,773.76 | 2020-2025 | Caplyta |
| Allergan, INC. | $3,964.65 | 2019-2020 | |
| Abbvie INC. | $3,360.98 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,199.16 | 2020-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $760.09 | 2019-2025 | Trintellix |
| Corium, LLC | $729.16 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $666.14 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $650.65 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $465.79 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $420.98 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $369.40 | 2019-2025 | Spravato, Invega Sustenna |
| Almatica Pharma LLC | $282.78 | 2024-2025 | Loreev Xr |
| Alkermes, INC. | $282.33 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $176.34 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $122.55 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $116.15 | 2020-2022 | |
| Neos Therapeutics, Lp | $74.39 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Supernus Pharmaceuticals, INC. | $60.10 | 2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $59.32 | 2025 | Cobenfy |
| Eisai INC. | $46.32 | 2021 | |
| Idorsia Pharmaceuticals US INC | $46.29 | 2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $39.58 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $35.96 | 2019-2020 | |
| Tms Neurohealth Centers INC. | $35.05 | 2025 | Tms Neurohealth Centers INC. |
| Tonix Medicines, INC. | $27.36 | 2025 | Tonmya |
| Shire North American Group INC | $27.20 | 2019 | |
| Indivior INC. | $23.49 | 2023 | Perseris |
| Merck Sharp & Dohme LLC | $20.49 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.73 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chervony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.